<p>Log2-transformed levels of MPO (A, C) and Fibrinogen (B, D) (ng/ml for MPO and mg/dl for Fibrinogen) are plotted against covariate adjusted values for FEV<sub>1</sub>/FVC and DLCO, respectively in COPD patients with (A, B) and without (C, D) metabolic syndrome (<i>r</i> values indicate spearman correlation, covariates include age, sex, BMI, pack years and smoking status).</p
<p>Data are mean ± SD or percentages or <sup>#</sup>median (interquartile range) if data were not no...
SummaryBackgroundRecent studies show that COPD patients exhibit low-grade systemic inflammation, and...
Background: COPD is a multicomponent disease and systemic inflammation represents one of the possibl...
The identification and validation of biomarkers to support the assessment of novel therapeutics for ...
The identification and validation of biomarkers to support the assessment of novel therapeutics for ...
The identification and validation of biomarkers to support the assessment of novel therapeutics for ...
<p>Significance (<i>p</i> values) and effect sizes (spearman correlation) are listed for biomarker a...
Chronic obstructive pulmonary disease (COPD) and metabolic syndrome represent common causes of morbi...
Cardiovascular and skeletal muscle manifestations constitute important comorbidities in COPD, with s...
BACKGROUND: There is a need for biomarkers to better characterise individuals with COPD and to aid w...
Background: Plasma metabolomics profile (PMP) in COPD has been associated with clinical characterist...
Cardiovascular and skeletal muscle manifestations constitute important comorbidities in COPD, with s...
<p>WC, waist circumference; HDL, high density lipoprotein; Syst BP, systolic blood pressure; Dia BP,...
SummaryObjectiveThere is great need of biomarkers for research and clinical purposes in COPD. This s...
Chronic obstructive pulmonary disease (COPD) is one of the world’s most common chronic diseases, and...
<p>Data are mean ± SD or percentages or <sup>#</sup>median (interquartile range) if data were not no...
SummaryBackgroundRecent studies show that COPD patients exhibit low-grade systemic inflammation, and...
Background: COPD is a multicomponent disease and systemic inflammation represents one of the possibl...
The identification and validation of biomarkers to support the assessment of novel therapeutics for ...
The identification and validation of biomarkers to support the assessment of novel therapeutics for ...
The identification and validation of biomarkers to support the assessment of novel therapeutics for ...
<p>Significance (<i>p</i> values) and effect sizes (spearman correlation) are listed for biomarker a...
Chronic obstructive pulmonary disease (COPD) and metabolic syndrome represent common causes of morbi...
Cardiovascular and skeletal muscle manifestations constitute important comorbidities in COPD, with s...
BACKGROUND: There is a need for biomarkers to better characterise individuals with COPD and to aid w...
Background: Plasma metabolomics profile (PMP) in COPD has been associated with clinical characterist...
Cardiovascular and skeletal muscle manifestations constitute important comorbidities in COPD, with s...
<p>WC, waist circumference; HDL, high density lipoprotein; Syst BP, systolic blood pressure; Dia BP,...
SummaryObjectiveThere is great need of biomarkers for research and clinical purposes in COPD. This s...
Chronic obstructive pulmonary disease (COPD) is one of the world’s most common chronic diseases, and...
<p>Data are mean ± SD or percentages or <sup>#</sup>median (interquartile range) if data were not no...
SummaryBackgroundRecent studies show that COPD patients exhibit low-grade systemic inflammation, and...
Background: COPD is a multicomponent disease and systemic inflammation represents one of the possibl...